Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.54 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.51 |
| ▸ | NPY2R | P49146 | 1/20 | 0.51 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23775506 | 0.87 | DRD2 (0.57) | DRD2SUCNR1SIGMAR1CACNA1G | |
| SCHEMBL23775742 | 0.86 | DRD2 (0.58) | DRD2SUCNR1SIGMAR1NPY2RCACNA1G | |
| SCHEMBL31301273 | 0.86 | DRD2 (0.64) | DRD2SUCNR1SIGMAR1FAAH | |
| SCHEMBL3440056 | 0.86 | DRD2 (0.64) | DRD2SUCNR1SIGMAR1FAAH | |
| SCHEMBL23775768 | 0.82 | DRD2 (0.57) | DRD2SUCNR1KMT2ASIGMAR1FAAH | |
| SCHEMBL34460001 | 0.82 | DRD2 (0.57) | DRD2SUCNR1KMT2ASIGMAR1FAAH | |
| SCHEMBL23142613 | 0.82 | FAAH (0.59) | KMT2ASIGMAR1CACNA1GCYP2D6CYP2C9 | |
| SCHEMBL8536087 | 0.80 | CYP2D6 (0.61) | KMT2ANPY2RCYP2D6CYP2C9ALOX15 | |
| SCHEMBL23775681 | 0.80 | DRD2 (0.69) | DRD2SUCNR1KMT2ASIGMAR1 | |
| SCHEMBL5729170 | 0.80 | CTSS (0.54) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3796900-B1 | TRITERPENE AMINE DERIVATIVES | DFH THERAPEUTICS (US) | 2026-04-08 | — | — | EP | disclosed |
| US-11236122-B2 | Triterpene amine derivatives | DFH THERAPEUTICS (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210253627-A1 | TRITERPENE AMINE DERIVATIVES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253627-A1 | TRITERPENE AMINE DERIVATIVES | BET1, PGGT1B, NFATC1 | DRD2 285/4885SUCNR1 2517/4885KMT2A 3133/4885 |
| US-11236122-B2 | Triterpene amine derivatives | BET1, PGGT1B, NFATC1 | DRD2 285/4885SUCNR1 2517/4885KMT2A 3133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.